"Carcinoma, Squamous Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
| Descriptor ID |
D002294
|
| MeSH Number(s) |
C04.557.470.200.400 C04.557.470.700.400
|
| Concept/Terms |
Carcinoma, Squamous Cell- Carcinoma, Squamous Cell
- Carcinomas, Squamous Cell
- Squamous Cell Carcinomas
- Squamous Cell Carcinoma
- Carcinoma, Squamous
- Carcinomas, Squamous
- Squamous Carcinoma
- Squamous Carcinomas
- Carcinoma, Epidermoid
- Carcinomas, Epidermoid
- Epidermoid Carcinoma
- Epidermoid Carcinomas
- Carcinoma, Planocellular
- Carcinomas, Planocellular
- Planocellular Carcinoma
- Planocellular Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Squamous Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Squamous Cell".
This graph shows the total number of publications written about "Carcinoma, Squamous Cell" by people in this website by year, and whether "Carcinoma, Squamous Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Squamous Cell" by people in Profiles.
-
"Very Late" isolated para-aortic nodal recurrence of carcinoma cervix mimicking radiation-induced sarcoma. J Cancer Res Ther. 2011 Jan-Mar; 7(1):78-80.
-
Cervical dysplasia: assessing methylation status (Methylight) of CCNA1, DAPK1, HS3ST2, PAX1 and TFPI2 to improve diagnostic accuracy. Gynecol Oncol. 2010 Nov; 119(2):225-31.
-
Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol. 2009 Jan; 4(1):12-21.